Wet Age-Related Macular Degeneration (Wet-AMD) Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelhe

DelveInsight's, "Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025" report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight's analysis indicates that the Wet Age-Related Macular Degeneration (Wet-AMD) pipeline involves over 60 key companies actively developing more than 70 therapies for Wet-AMD treatment.

Wet Age-Related Macular Degeneration (Wet-AMD) Overview:

Wet Age-related Macular Degeneration (AMD) is a chronic eye condition affecting the macula, the central part of the retina responsible for sharp, detailed vision. It is the more aggressive form of AMD compared to the dry type and can progress rapidly, potentially causing significant vision loss if untreated. This form occurs when abnormal blood vessels grow beneath the macula, leaking blood or fluid that disrupts retinal function and leads to scarring. Wet AMD primarily affects individuals over 50 and is a leading cause of central vision impairment in older adults.

Early symptoms often include blurry or distorted central vision, making tasks like reading, recognizing faces, or performing fine work difficult. Straight lines may appear bent or wavy, a condition called metamorphopsia, and dark or blank spots (scotomas) can appear in the central field of vision. Symptoms often arise suddenly and may worsen quickly, although peripheral vision typically remains unaffected.

Wet AMD develops due to abnormal growth of blood vessels (angiogenesis) beneath the retina, often driven by excessive production of vascular endothelial growth factor (VEGF). While the exact cause is not fully understood, risk factors include age, family history, smoking, obesity, hypertension, and a diet low in antioxidants. Environmental factors, such as prolonged exposure to ultraviolet (UV) light, may also contribute to retinal damage.

Diagnosis involves a comprehensive eye exam, including visual acuity testing and retinal examination after pupil dilation. Optical coherence tomography (OCT) is frequently used to capture high-resolution, cross-sectional images of the retina to detect fluid buildup or swelling. Fluorescein angiography may also be employed, where a dye is injected into the bloodstream to highlight abnormal retinal blood vessels.

Request for a detailed insights report on Wet Age-Related Macular Degeneration (Wet-AMD) pipeline insights [https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Wet Age-Related Macular Degeneration (Wet-AMD) Therapeutics Market.

Key Takeaways from the Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Report

DelveInsight's Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report highlights a vibrant landscape, with over 60 active companies developing more than 70 therapies for Wet-AMD treatment.

Key companies in this space include Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate, and others, all actively evaluating new drugs to improve treatment outcomes for Wet-AMD.

Prominent pipeline candidates under development include ONS-5010, OPT-302, SYL1801, BI 836880, and others.

Recent updates include:

*
March 2025: Teva Pharmaceutical Industries and Alvotech announced that the FDA will review their biosimilar candidate, AVT06, positioned as a potential alternative to Regeneron's Eylea (aflibercept). The introduction of biosimilars like AVT06 could expand treatment options and potentially lower costs for patients.

*
ABBV-RGX-314, developed by Regenxbio in collaboration with AbbVie, is an investigational gene therapy aimed at providing a potential one-time treatment for Wet-AMD and other retinal conditions. It is currently in Phase II clinical trials, exploring both subretinal and suprachoroidal delivery methods.

Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Wet Age-Related Macular Degeneration (Wet-AMD) Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration (Wet-AMD) treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Wet Age-Related Macular Degeneration (Wet-AMD) market.

Download our free sample page report on Wet Age-Related Macular Degeneration (Wet-AMD) pipeline insights [https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs

*
ONS-5010: Outlook Therapeutics

*
OPT-302: Opthea

*
SYL1801: Sylentis

*
BI 836880: Boehringer Ingelheim

Wet Age-Related Macular Degeneration (Wet-AMD) Companies

More than 60 leading companies are actively developing therapies for Wet Age-Related Macular Degeneration (Wet-AMD), with Outlook Therapeutics advancing a drug candidate to the Phase III stage, the most advanced in development.

DelveInsight's report covers around 70+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Wet Age-Related Macular Degeneration (Wet-AMD) Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Wet Age-Related Macular Degeneration (Wet-AMD) Therapies and Key Companies: Wet Age-Related Macular Degeneration (Wet-AMD) Clinical Trials and advancements [https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Therapeutic Assessment

- Wet Age-Related Macular Degeneration (Wet-AMD) Assessment by Product Type

- Wet Age-Related Macular Degeneration (Wet-AMD) By Stage

- Wet Age-Related Macular Degeneration (Wet-AMD) Assessment by Route of Administration

- Wet Age-Related Macular Degeneration (Wet-AMD) Assessment by Molecule Type

Download Wet Age-Related Macular Degeneration (Wet-AMD) Sample report to know in detail about the Wet Age-Related Macular Degeneration (Wet-AMD) treatment market @ Wet Age-Related Macular Degeneration (Wet-AMD) Therapeutic Assessment [https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Wet Age-Related Macular Degeneration (Wet-AMD) Current Treatment Patterns

4. Wet Age-Related Macular Degeneration (Wet-AMD) - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Wet Age-Related Macular Degeneration (Wet-AMD) Late-Stage Products (Phase-III)

7. Wet Age-Related Macular Degeneration (Wet-AMD) Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Wet Age-Related Macular Degeneration (Wet-AMD) Discontinued Products

13. Wet Age-Related Macular Degeneration (Wet-AMD) Product Profiles

14. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies

15. Wet Age-Related Macular Degeneration (Wet-AMD) Key Products

16. Dormant and Discontinued Products

17. Wet Age-Related Macular Degeneration (Wet-AMD) Unmet Needs

18. Wet Age-Related Macular Degeneration (Wet-AMD) Future Perspectives

19. Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Reports Offerings [https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=wet-agerelated-macular-degeneration-wetamd-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-outlook-therapeutics-opthea-sylentis-boehringer-ingelhe]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.